However, it remains uncertain whether the alternative—unstructured clinical approaches without the use of risk-assessment tools—lead to improved prediction and outcomes. It has been argued that such tools also provide a useful baseline assessment, a checklist to identify risk factors, and can be li...
We evaluated patient-reported outcomes including HRQOL outcomes following adalimumab plus methotrexate (MTX) therapy in patients with early RA.PREMIER was a phase III, multicenter, randomized...
TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01686802 . 2017 Canadian Medical Association or its licensors.doi:10.1503/cmaj.170017Poonai, NaveenDatoo, NatashaAli, SaminaCashin, MeganDrendel...